文献速递淋巴瘤

间变性大细胞淋巴瘤的神经脑膜复发:发生率、危险因素与预后——欧洲儿童非霍奇金淋巴瘤协作组报告

Neuro-meningeal relapse in anaplastic large-cell lymphoma: incidence, risk factors and prognosis - a report from the European intergroup for childhood non-Hodgkin lymphoma.
PubMed 文献 · Br J Haematol · 2020-07-09

该研究分析ALCL99数据库中618例ALK+间变性大细胞淋巴瘤(ALCL)患者,中位随访8年,26例在首次或后续复发时累及中枢神经系统(CNS)。5年CNS复发累积风险为4%(95% CI 2.9-5.5),诊断时骨髓受累、外周原始细胞和CNS受累在CNS复发患者中更常见。CNS复发后中位生存23.7个月,3年总生存率48.70%(95% CI 30.52-67.23)。

要点

  • ALK+ALCL患者CNS复发罕见,5年累积风险为4%(95% CI 2.9-5.5)。
  • 诊断时骨髓受累、外周原始细胞和CNS受累与后续CNS复发相关。
  • CNS复发后3年总生存率为48.70%(95% CI 30.52-67.23)。

核心结论

  • 接受含CNS预防方案治疗的ALK+ALCL儿童和青少年中CNS复发罕见,5年累积风险为4%(95% CI 2.9-5.5)。
  • 诊断时骨髓受累、外周原始细胞和CNS受累在CNS复发患者中更频繁出现。
  • CNS复发后中位生存为23.7个月,3年总生存率为48.70%(95% CI 30.52-67.23)。

研究设计与样本

  • 研究分析ALCL99数据库中所有发生CNS复发的ALK+ALCL患者的临床与组织学数据。
  • 共纳入618例患者,其中26例在首次或后续复发时报告CNS受累。
  • 比较无复发、无CNS受累复发和CNS复发三组患者的特征。
  • 中位随访8年(范围0.05-18年)。

主要发现

  • 26/618例患者在首次或后续复发时报告CNS受累。
  • 从初诊至首次CNS复发的中位间隔为8个月(IQR 5.55-10.61,范围1.31-130.69)。
  • 5年CNS复发累积风险为4%(95% CI 2.9-5.5)。
  • 诊断时骨髓受累、外周原始细胞和CNS受累在CNS复发患者中较无复发或无CNS受累复发患者更常见。
  • CNS复发后中位生存为23.7个月,末次随访时11例存活,CNS复发后3年总生存率为48.70%(95% CI 30.52-67.23)。

临床怎么用

  • CNS复发治疗方案异质,原文未据此给出统一推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapses involving the central nervous system (CNS) are rare in children and adolescents with ALK+ anaplastic large cell lymphoma (ALCL) treated with regimens including CNS prophylaxis. Early identification of patients at high-risk for CNS relapse would enable stratification and better adaptation of initial treatment especially in the light of the upcoming targeted therapies with limited CNS penetration. We analyzed clinical and histological data of all ALK+ALCL patients with CNS relapse registered in ALCL99-database with the aim to describe risk factors and outcome. Characteristics of patients with no relapse, relapse without CNS involvement and CNS relapse were compared. At a median follow-up of 8 years (0.05-18 years), a CNS involvement was reported at first or subsequent relapse in 26/618 patients. Median interval between initial diagnosis and first CNS relapse was 8 months (IQR 5.55-10.61/range 1.31-130.69). The 5-year cumulative risk of CNS relapse was 4% (95% CI 2.9-5.5). Bone marrow involvement, peripheral blasts and CNS involvement at diagnosis were more frequent in patients with CNS relapse than in patients with no relapse or with relapse with no CNS involvement. The treatment of CNS relapse was heterogeneous. The median survival after CNS relapse was 23.7 months. Eleven patients were alive at last follow-up. Three-year overall survival after CNS relapse was 48.70% (95% CI 30.52-67.23).

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Del Baldo G, Abbas R, Woessmann W, et al. Neuro-meningeal relapse in anaplastic large-cell lymphoma: incidence, risk factors and prognosis - a report from the European intergroup for childhood non-Hodgkin lymphoma. Br J Haematol. 2020. PMID: 32648260. doi:10.1111/bjh.16755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。